Table 3 Building multivariable Cox regression with TIMM17A and NMT1 on overall survival. The complete model adjusted for gender, age, tumoral stage, and presence of KRAS, STK11, KEAP1 mutations showed that both high TIMM17A and high NMT1 were associated with worse OS (TIMM17A: P = 0.005, HR = 1.56 [95% CI: 1.14, 2.14] and NMT1: P = 0.023, HR = 1.51 [95% CI: 1.06, 1.14]).

From: Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer

 

Overall survival

HR (95% CI)

P value

Model 1: Initial model

  

TIMM17A: Low vs. high

1.60 (1.17, 2.18)

0.003**

NMT1: Low vs. high

1.53 (1.08, 2.15)

0.016*

Gender: Female vs. male

1.01 (0.74, 1.37)

0.942

Age

1.01 (0.99, 1.02)

0.540

n = 484, n-events = 174

  

Adding stage

Overall survival

HR (95% CI)

P value

Model 2: Ordinal stage

TIMM17A: Low vs. high

1.48 (1.10, 1.99)

0.010**

NMT1: Low vs. high

1.48 (1.07, 2.07)

0.019*

Stage: Ordinal

1.67 (1.45, 1.92)

< 0.001***

Model 3: Stage I/II vs. III/IV

TIMM17A: Low vs. high

1.48 (1.10, 1.99)

0.010*

NMT1: Low vs. high

1.57 (1.12, 2.18)

0.008**

Stage: I/II vs. III/IV

2.68 (1.96, 3.64)

< 0.001***

n = 498, n-events = 181

  

Adding hypoxia score

Overall Survival

HR (95% CI)

P value

Model 4: Hypoxia score

TIMM17A: Low vs. high

1.30 (0.96, 1.77)

0.092

NMT1: Low vs. high

1.35 (0.96, 1.91)

0.084

Stage: I/II vs. III/IV

2.56 (1.87, 3.49)

< 0.001***

Buffa hypoxia score (scaled)

1.29 (1.10, 1.52)

0.002**

n = 493, n-events = 179

  
 

Overall survival

HR (95% CI)

P value

Complete model

TIMM17A: Low vs. high

1.56 (1.14, 2.14)

0.005**

NMT1: Low vs. high

1.51 (1.06, 2.14)

0.023*

Gender: Female vs. male

0.92 (0.68, 1.26)

0.608

Age

1.06 (0.90, 1.24)

0.495

Stage: I/II vs. III/IV

2.65 (1.92, 3.65)

< 0.001***

KRAS

0.86 (0.54, 1.37)

0.533

KEAP1

0.96 (0.59, 1.57)

0.866

STK11

1.62 (0.96, 2.72)

0.069

n = 477, n-events = 172

  
Back to article page